Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911557 · ClinicalTrials.gov registry record · Phase 2
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
A Phase 2 study, sponsored by John L. Villano, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03911557 is a Phase 2 study that has completed, run by John L. Villano, MD, PhD. The registered enrollment target is 14 participants.
The verdict
NCT03911557, a Phase 2 study, has completed, sponsored by John L. Villano, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free survival with dual Tremelimumab and Durvalumab treatment.
Interventions
- DRUG Durvalumab and Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-08 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03911557
The ClinicalTrials.gov registry entry for NCT03911557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John L. Villano, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Durvalumab and Tremelimumab is the first listed.
NCT03911557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03911557 about?
NCT03911557 is a clinical study titled "Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors". This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free survival with dual Tremelimumab and Durvalumab treatment.
What is the current status of trial NCT03911557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2019-06-08. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT03911557?
The interventions under investigation include: Durvalumab and Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03911557?
This trial is sponsored by John L. Villano, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.